CN109069641A - 用于治疗家族性高胆固醇血症患者的方法 - Google Patents

用于治疗家族性高胆固醇血症患者的方法 Download PDF

Info

Publication number
CN109069641A
CN109069641A CN201780026147.XA CN201780026147A CN109069641A CN 109069641 A CN109069641 A CN 109069641A CN 201780026147 A CN201780026147 A CN 201780026147A CN 109069641 A CN109069641 A CN 109069641A
Authority
CN
China
Prior art keywords
lipid
statin
angptl3
antibody
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780026147.XA
Other languages
English (en)
Chinese (zh)
Inventor
R·C·波尔蒂
W·J·萨赛拉
D·A·施韦默尔-吉普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CN109069641A publication Critical patent/CN109069641A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780026147.XA 2016-04-28 2017-04-27 用于治疗家族性高胆固醇血症患者的方法 Pending CN109069641A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662328823P 2016-04-28 2016-04-28
US62/328,823 2016-04-28
US201662348001P 2016-06-09 2016-06-09
US62/348,001 2016-06-09
US201762451310P 2017-01-27 2017-01-27
US62/451,310 2017-01-27
PCT/US2017/029782 WO2017189813A1 (en) 2016-04-28 2017-04-27 Methods for treating patients with familial hypercholesterolemia

Publications (1)

Publication Number Publication Date
CN109069641A true CN109069641A (zh) 2018-12-21

Family

ID=58692626

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780026147.XA Pending CN109069641A (zh) 2016-04-28 2017-04-27 用于治疗家族性高胆固醇血症患者的方法

Country Status (24)

Country Link
US (4) US20170312359A1 (enExample)
EP (1) EP3448426B1 (enExample)
JP (2) JP7201437B2 (enExample)
KR (3) KR20240019856A (enExample)
CN (1) CN109069641A (enExample)
AU (1) AU2017258105B2 (enExample)
CA (1) CA3021884A1 (enExample)
DK (1) DK3448426T3 (enExample)
ES (1) ES3032667T3 (enExample)
FI (1) FI3448426T3 (enExample)
HR (1) HRP20250797T1 (enExample)
HU (1) HUE071912T2 (enExample)
IL (2) IL293308B2 (enExample)
LT (1) LT3448426T (enExample)
MA (1) MA44764B1 (enExample)
MD (1) MD3448426T2 (enExample)
MX (1) MX2018012741A (enExample)
PL (1) PL3448426T3 (enExample)
PT (1) PT3448426T (enExample)
RS (1) RS66975B1 (enExample)
SI (1) SI3448426T1 (enExample)
SM (1) SMT202500230T1 (enExample)
WO (1) WO2017189813A1 (enExample)
ZA (1) ZA201806557B (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112656792A (zh) * 2021-01-26 2021-04-16 首都医科大学宣武医院 洛美他派在制备用于治疗脑卒中引起的神经损伤药物中的新用途
CN114650839A (zh) * 2019-11-07 2022-06-21 麦迪穆医学免疫有限责任公司 用于治疗心血管疾病的内皮脂肪酶抗体
CN116096365A (zh) * 2020-08-07 2023-05-09 瑞泽恩制药公司 涉及angptl3抑制剂的治疗难治性高胆固醇血症的方法
CN116322682A (zh) * 2020-07-29 2023-06-23 艾米琳制药有限责任公司 在治疗儿科患者的高脂血症和高胆固醇血症的方法中使用的洛美他派
WO2023207780A1 (zh) * 2022-04-25 2023-11-02 武汉大学 抗asgr1单克隆抗体及其应用
WO2025002047A1 (zh) * 2023-06-25 2025-01-02 百奥泰生物制药股份有限公司 抗angptl3抗体及其应用

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
MA43734A (fr) 2016-03-03 2018-11-28 Regeneron Pharma Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3
US11414661B2 (en) 2017-12-01 2022-08-16 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
WO2019105418A1 (zh) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途
JP7365052B2 (ja) 2017-12-01 2023-10-19 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
KR102834361B1 (ko) 2017-12-01 2025-07-17 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 핵산, 이를 포함하는 조성물과 컨쥬게이트, 및 그의 제조 방법과 용도
US11414665B2 (en) 2017-12-01 2022-08-16 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
CA3087106A1 (en) 2017-12-29 2019-07-04 Suzhou Ribo Life Science Co., Ltd. Conjugates and preparation and use thereof
JP2021533800A (ja) 2018-08-21 2021-12-09 スーチョウ リボ ライフ サイエンス カンパニー、リミテッドSuzhou Ribo Life Science Co., Ltd. 核酸、当該核酸を含む薬物組成物及び複合体ならびにその使用
CN111655297A (zh) 2018-09-30 2020-09-11 苏州瑞博生物技术有限公司 一种siRNA缀合物及其制备方法和用途
CN112423795A (zh) * 2018-12-28 2021-02-26 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
WO2021154079A1 (en) 2020-01-29 2021-08-05 Rijksuniversiteit Groningen Means and methods for modulating lipid metabolism
IL316249A (en) 2022-05-02 2024-12-01 Novo Nordisk As Novel anti-angptl3 antibodies suitable for high concentration compositions and subcutaneous administration

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1505502A (zh) * 2001-02-22 2004-06-16 ˹����ҩƷ���ô�˾ 具有减少进食-禁食作用的贝特-它汀组合
CN101855241A (zh) * 2006-12-08 2010-10-06 莱克康制药公司 针对angptl3的单克隆抗体
CN102341095A (zh) * 2009-02-06 2012-02-01 力奇制药公司 包含依泽麦布的药物组合物的制备方法
CN102753186A (zh) * 2010-01-08 2012-10-24 Isis制药公司 血管生成素样3表达的调节
US20130064834A1 (en) * 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
CN103732624A (zh) * 2011-06-17 2014-04-16 瑞泽恩制药公司 抗angptl3抗体及其用途
WO2015077154A1 (en) * 2013-11-20 2015-05-28 Cymabay Therapeutics, Inc. Treatment of homozygous familial hypercholesterolemia
WO2015100394A1 (en) * 2013-12-24 2015-07-02 Isis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US730654A (en) * 1902-04-17 1903-06-09 John W Hornsey Hot-air furnace.
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2012168491A1 (en) 2011-06-10 2012-12-13 Novartis Ag Pharmaceutical formulations of pcsk9 antagonists
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
SI3137605T1 (sl) * 2014-05-01 2021-02-26 Ionis Pharmaceuticals, Inc. Sestavki in metode za modulacijo ekspresije angiopoetin 3-podobnega
MA43734A (fr) * 2016-03-03 2018-11-28 Regeneron Pharma Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3
LT3439689T (lt) * 2016-04-08 2021-11-10 Regeneron Pharmaceuticals, Inc. Hiperlipidemijos gydymo būdai angptl8 inhibitoriumi ir angptl3 inhibitoriumi

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1505502A (zh) * 2001-02-22 2004-06-16 ˹����ҩƷ���ô�˾ 具有减少进食-禁食作用的贝特-它汀组合
CN101855241A (zh) * 2006-12-08 2010-10-06 莱克康制药公司 针对angptl3的单克隆抗体
US20130064834A1 (en) * 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
CN102341095A (zh) * 2009-02-06 2012-02-01 力奇制药公司 包含依泽麦布的药物组合物的制备方法
CN102753186A (zh) * 2010-01-08 2012-10-24 Isis制药公司 血管生成素样3表达的调节
CN103732624A (zh) * 2011-06-17 2014-04-16 瑞泽恩制药公司 抗angptl3抗体及其用途
WO2015077154A1 (en) * 2013-11-20 2015-05-28 Cymabay Therapeutics, Inc. Treatment of homozygous familial hypercholesterolemia
WO2015100394A1 (en) * 2013-12-24 2015-07-02 Isis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
VIKTORIA GUSAROVA ET AL.: ""ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys"", 《JOURNAL OF LIPID RESEARCH》 *
张宝玉等: ""人血管生成素样蛋白3 与糖尿病血管病变和血脂紊乱相关性研究"", 《临床医药实践》 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114650839A (zh) * 2019-11-07 2022-06-21 麦迪穆医学免疫有限责任公司 用于治疗心血管疾病的内皮脂肪酶抗体
CN116322682A (zh) * 2020-07-29 2023-06-23 艾米琳制药有限责任公司 在治疗儿科患者的高脂血症和高胆固醇血症的方法中使用的洛美他派
US12472172B2 (en) 2020-07-29 2025-11-18 Amryt Pharmaceuticals Inc. Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients
CN116096365A (zh) * 2020-08-07 2023-05-09 瑞泽恩制药公司 涉及angptl3抑制剂的治疗难治性高胆固醇血症的方法
CN112656792A (zh) * 2021-01-26 2021-04-16 首都医科大学宣武医院 洛美他派在制备用于治疗脑卒中引起的神经损伤药物中的新用途
CN112656792B (zh) * 2021-01-26 2022-07-05 首都医科大学宣武医院 洛美他派在制备用于治疗脑卒中引起的神经损伤药物中的用途
WO2023207780A1 (zh) * 2022-04-25 2023-11-02 武汉大学 抗asgr1单克隆抗体及其应用
WO2025002047A1 (zh) * 2023-06-25 2025-01-02 百奥泰生物制药股份有限公司 抗angptl3抗体及其应用

Also Published As

Publication number Publication date
IL293308B1 (en) 2024-08-01
IL262591B (en) 2022-07-01
JP2019514907A (ja) 2019-06-06
WO2017189813A1 (en) 2017-11-02
DK3448426T3 (da) 2025-06-30
PT3448426T (pt) 2025-06-04
MD3448426T2 (ro) 2025-09-30
SI3448426T1 (sl) 2025-07-31
US20230000976A1 (en) 2023-01-05
AU2017258105B2 (en) 2024-09-05
HUE071912T2 (hu) 2025-10-28
IL262591A (en) 2018-12-31
KR20190003679A (ko) 2019-01-09
JP7201437B2 (ja) 2023-01-10
CA3021884A1 (en) 2017-11-02
LT3448426T (lt) 2025-07-10
PL3448426T3 (pl) 2025-08-04
FI3448426T3 (fi) 2025-07-18
US20170312359A1 (en) 2017-11-02
IL293308A (en) 2022-07-01
HRP20250797T1 (hr) 2025-08-29
SMT202500230T1 (it) 2025-07-22
ZA201806557B (en) 2019-07-31
AU2017258105A1 (en) 2018-11-22
IL293308B2 (en) 2024-12-01
US20200061189A1 (en) 2020-02-27
US20250332254A1 (en) 2025-10-30
EP3448426B1 (en) 2025-05-28
JP2022177142A (ja) 2022-11-30
MA44764A (fr) 2019-03-06
KR20220148299A (ko) 2022-11-04
MX2018012741A (es) 2019-05-16
ES3032667T3 (en) 2025-07-23
KR20240019856A (ko) 2024-02-14
RS66975B1 (sr) 2025-07-31
MA44764B1 (fr) 2025-09-30
JP7404471B2 (ja) 2023-12-25
EP3448426A1 (en) 2019-03-06

Similar Documents

Publication Publication Date Title
CN109069641A (zh) 用于治疗家族性高胆固醇血症患者的方法
JP6158813B2 (ja) プロタンパク質転換酵素サブチリシンケキシン−９（ＰＣＳＫ９）の阻害剤を投与することによってリポタンパク質（ａ）レベルを低下させる方法
KR102860143B1 (ko) Angptl3의 억제제를 투여함으로써 죽상 동맥경화증을 치료하거나 예방하기 위한 방법
KR20180132843A (ko) Angptl8 억제제 및 angptl3 억제제로 고지혈증을 치료하는 방법
CN103314011A (zh) 胰高血糖素受体的人抗体
CN107922507B (zh) 抗pcsk9抑制性抗体用来治疗接受脂蛋白单采的高脂血症患者
EP3882273A1 (en) Dosing regimens for use with pcsk9 inhibitors
CN109069868B (zh) 通过施用与angptl3抑制剂组合的pcsk9抑制剂治疗高脂血症患者的方法
WO2015140079A1 (en) Methods for treating subjects with primary hypercholesterolemia that is not adequately controlled
US20240197870A1 (en) Methods for treating patients with refractory hypercholesterolemia
JP2020037566A (ja) Ｐｃｓｋ９阻害剤と共に使用するための投薬レジメン
HK40003056B (en) Methods for treating patients with familial hypercholesterolemia
HK40003056A (en) Methods for treating patients with familial hypercholesterolemia
HK40059806A (en) Dosing regimens for use with pcsk9 inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination